91Curated trials
Enterprise Evidence Report · NR-REPORT-V2.0
Finland
Neuroscience Intelligence
Finland neuroscience evidence report: current clinical, research, institution and source-linked intelligence.
Evidence rank #26 of 50 · Data maturity A · Research score 35.8 · Data confidence 100.0 / 100 · Snapshot 2026-10-29 06:18 UTC.
22Recruiting trials
100Publications
54Institutions
Executive interpretation
Finland ranks #26 in the current NeuroRisk evidence-ranked market layer. This ranking summarizes indexed clinical, publication and institution evidence; it is not a probability of commercial success and not an investment recommendation.
Methodology status
Methodology NR-REPORT-V2.0. Clinical metrics and NCT evidence use only records classified as in_scope or related; out_of_scope records remain preserved outside these analytical counts. No synthetic ML confidence is presented as scientific probability. Counts and source links below are tied to the generation snapshot.
Methodology →Leading sponsors
Merck Sharp & Dohme LLC97 recruiting
Boehringer Ingelheim60 recruiting
Hoffmann-La Roche60 recruiting
Novartis Pharmaceuticals41 recruiting
Helsinki University Central Hospital40 recruiting
UCB Pharma30 recruiting
Pfizer30 recruiting
Orion Corporation, Orion Pharma30 recruiting
Turku University Hospital31 recruiting
Bristol-Myers Squibb20 recruiting
Disease activity
Alzheimers22trials
Parkinsons18trials
Epilepsy14trials
Stroke10trials
Other Neurology4trials
Depression4trials
Schizophrenia4trials
Other Psychiatry2trials
Sleep Disorders2trials
Pain Neuropathy2trials
Research institutions
Finnish Coeliac SocietyOpenAlexlinked institution
Lappeenranta-Lahti University of TechnologyOpenAlexlinked institution
Glaxosmithkline (Finland)OpenAlexlinked institution
Finnish Literature SocietyOpenAlexlinked institution
Research Council of FinlandOpenAlexlinked institution
Satakunta Central HospitalOpenAlexlinked institution
Hospital District of Helsinki and UusimaaOpenAlexlinked institution
Specim (Finland)OpenAlexlinked institution
Finnish Meteorological InstituteOpenAlexlinked institution
Pirkanmaa Hospital DistrictOpenAlexlinked institution
Clinical evidence trail
NCT07502560A Study to Evaluate the Effect of Recombinant Zoster Vaccine on New Diagnosis of Dementia in an Older Adult Population Aged 76 Years or Older in FinlandRECRUITING
NCT07252739KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)RECRUITING
NCT07208825The Effectiveness of Conservative Treatment in Patients With Complex Regional Pain Syndrome.RECRUITING
NCT06966700A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)RECRUITING
NCT06952504A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)RECRUITING
NCT06460363Transcranial Alternating Current Stimulation on Patients with Delirium and Critical Illness (DeliTACS)RECRUITING
NCT06298552A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia GravisACTIVE_NOT_RECRUITING
NCT06127459Virtual Reality in Rehabilitation of Executive Functions in Children With Mild or Moderate Traumatic Brain InjuryRECRUITING
Research evidence trail
PUBMEDChanges in the use of vitamin K antagonists and direct oral anticoagulants and impact on the incidence of oral anticoagulation-related intracerebral hemorrhage: population-wide prescription patterns in two 5-year cohorts.2026-12-01
PUBMEDZero echo time imaging-based skull density ratio for high-intensity focused ultrasound.2026-12-01
PUBMEDInvestigating the effects of missense mutations on the dual Ras/Rap activation mechanism of SYNGAP1 using molecular modelling.2026-12-01
PUBMEDAdolescent anorexia nervosa treated in primary care with a family-based method - long-term outcomes.2026-12-01
PUBMEDIntravenous Ketamine reduces psychological pain in suicidal inpatients: A secondary analysis of a six-week randomized placebo-controlled trial.2026-12-01
PUBMEDNo evidence of increased gaming-related problems with long-term use of a video game therapeutic: Exploratory endpoint findings from a randomized controlled trial.2026-12-01
PUBMEDRole of resilience in modifying the links between genetic propensity for mental disorders and irritability.2026-11-15
PUBMEDRepetitive circadian disruption contributes to pain hypersensitivity and alters the transcriptional rhythms in spinal cord in male mice with neuropathic pain.2026-11-03
World Bank context
Macro indicators are shown only where a timestamped World Bank source row exists. Latest collection in this report: 2026-10-24 04:18 UTC. They are context, not NeuroRisk predictions.
Sources and provenance
ClinicalTrials.gov provides NCT evidence. PubMed/NCBI and OpenAlex provide research metadata. OpenAlex links institutions. World Bank indicators are included only when an explicit source row and year exist. NeuroRisk transformations add normalization, ranking and graph connections.
Limitations
Indexed corpus counts are not guaranteed exhaustive global totals. Scores are comparative decision-support signals. This report is not medical advice, regulatory advice, patent clearance, an investment recommendation or a guarantee of outcome.